Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Correction to: Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis.

Kwak M, Song Y, Gimotty PA, Farrow NE, Tieniber AD, Davick JG, Tortorello GN, Beasley GM, Slingluff CL Jr, Karakousis GC.

Ann Surg Oncol. 2019 Oct 31. doi: 10.1245/s10434-019-08046-8. [Epub ahead of print]

PMID:
31673939
2.

The Barrier Molecules Junction Plakoglobin, Filaggrin, and Dystonin Play Roles in Melanoma Growth and Angiogenesis.

Leick KM, Rodriguez AB, Melssen MM, Benamar M, Lindsay RS, Eki R, Du KP, Parlak M, Abbas T, Engelhard VH, Slingluff CL Jr.

Ann Surg. 2019 Oct;270(4):712-722. doi: 10.1097/SLA.0000000000003522.

PMID:
31425296
3.

Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis.

Kwak M, Song Y, Gimotty PA, Farrow NE, Tieniber AD, Davick JG, Tortorello GN, Beasley GM, Slingluff CL Jr, Karakousis GC.

Ann Surg Oncol. 2019 Nov;26(12):3962-3971. doi: 10.1245/s10434-019-07694-0. Epub 2019 Aug 7. Erratum in: Ann Surg Oncol. 2019 Oct 31;:.

PMID:
31392529
4.

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund's adjuvant in melanoma patients.

Melssen MM, Petroni GR, Chianese-Bullock KA, Wages NA, Grosh WW, Varhegyi N, Smolkin ME, Smith KT, Galeassi NV, Deacon DH, Gaughan EM, Slingluff CL Jr.

J Immunother Cancer. 2019 Jun 27;7(1):163. doi: 10.1186/s40425-019-0625-x.

5.

Patterns of immune-cell infiltration in murine models of melanoma: roles of antigen and tissue site in creating inflamed tumors.

Leick KM, Pinczewski J, Mauldin IS, Young SJ, Deacon DH, Woods AN, Bosenberg MW, Engelhard VH, Slingluff CL Jr.

Cancer Immunol Immunother. 2019 Jul;68(7):1121-1132. doi: 10.1007/s00262-019-02345-5. Epub 2019 May 27.

PMID:
31134297
6.

Bariatric surgery is independently associated with a decrease in the development of colorectal lesions.

Kwak M, Mehaffey JH, Hawkins RB, Hedrick TL, Slingluff CL Jr, Schirmer B, Hallowell PT, Friel CM.

Surgery. 2019 Sep;166(3):322-326. doi: 10.1016/j.surg.2019.03.013. Epub 2019 May 13.

PMID:
31097317
7.

Vaccine Strategy in Melanoma.

Kwak M, Leick KM, Melssen MM, Slingluff CL Jr.

Surg Oncol Clin N Am. 2019 Jul;28(3):337-351. doi: 10.1016/j.soc.2019.02.003. Epub 2019 Apr 15. Review.

PMID:
31079792
8.

Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells.

Gemta LF, Siska PJ, Nelson ME, Gao X, Liu X, Locasale JW, Yagita H, Slingluff CL Jr, Hoehn KL, Rathmell JC, Bullock TNJ.

Sci Immunol. 2019 Jan 25;4(31). pii: eaap9520. doi: 10.1126/sciimmunol.aap9520.

9.

Updates in adjuvant systemic therapy for melanoma.

Kwak M, Farrow NE, Salama AKS, Mosca PJ, Hanks BA, Slingluff CL, Beasley GM.

J Surg Oncol. 2019 Jan;119(2):222-231. doi: 10.1002/jso.25298. Epub 2018 Nov 27. Review.

PMID:
30481375
10.

Formation and phenotypic characterization of CD49a, CD49b and CD103 expressing CD8 T cell populations in human metastatic melanoma.

Melssen MM, Olson W, Wages NA, Capaldo BJ, Mauldin IS, Mahmutovic A, Hutchison C, Melief CJM, Bullock TN, Engelhard VH, Slingluff CL Jr.

Oncoimmunology. 2018 Aug 6;7(10):e1490855. doi: 10.1080/2162402X.2018.1490855. eCollection 2018.

11.

Academic or community practice? What is driving decision-making and career choices.

Goudreau BJ, Hassinger TE, Hedrick TL, Slingluff CL Jr, Schroen AT, Dengel LT.

Surgery. 2018 Sep;164(3):571-576. doi: 10.1016/j.surg.2018.05.003. Epub 2018 Jun 19.

12.

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.

Sullivan RJ, Atkins MB, Kirkwood JM, Agarwala SS, Clark JI, Ernstoff MS, Fecher L, Gajewski TF, Gastman B, Lawson DH, Lutzky J, McDermott DF, Margolin KA, Mehnert JM, Pavlick AC, Richards JM, Rubin KM, Sharfman W, Silverstein S, Slingluff CL Jr, Sondak VK, Tarhini AA, Thompson JA, Urba WJ, White RL, Whitman ED, Hodi FS, Kaufman HL.

J Immunother Cancer. 2018 May 30;6(1):44. doi: 10.1186/s40425-018-0362-6.

13.

Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures.

Stowman AM, Hickman AW, Mauldin IS, Mahmutovic A, Gru AA, Slingluff CL Jr.

Melanoma Res. 2018 Jun;28(3):237-245. doi: 10.1097/CMR.0000000000000439.

14.

Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer.

Knapp KA, Pires ES, Adair SJ, Mandal A, Mills AM, Olson WC, Slingluff CL Jr, Parsons JT, Bauer TW, Bullock TN, Herr JC.

Oncotarget. 2018 Jan 4;9(10):8972-8984. doi: 10.18632/oncotarget.23944. eCollection 2018 Feb 6.

15.

Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.

Engelhard VH, Rodriguez AB, Mauldin IS, Woods AN, Peske JD, Slingluff CL Jr.

J Immunol. 2018 Jan 15;200(2):432-442. doi: 10.4049/jimmunol.1701269. Review.

16.

CD47 Blockade as an Adjuvant Immunotherapy for Resectable Pancreatic Cancer.

Michaels AD, Newhook TE, Adair SJ, Morioka S, Goudreau BJ, Nagdas S, Mullen MG, Persily JB, Bullock TNJ, Slingluff CL Jr, Ravichandran KS, Parsons JT, Bauer TW.

Clin Cancer Res. 2018 Mar 15;24(6):1415-1425. doi: 10.1158/1078-0432.CCR-17-2283. Epub 2017 Dec 29.

17.

A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.

Dillon PM, Petroni GR, Smolkin ME, Brenin DR, Chianese-Bullock KA, Smith KT, Olson WC, Fanous IS, Nail CJ, Brenin CM, Hall EH, Slingluff CL Jr.

J Immunother Cancer. 2017 Nov 21;5(1):92. doi: 10.1186/s40425-017-0295-5.

18.

Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?

Obeid JM, Kunk PR, Zaydfudim VM, Bullock TN, Slingluff CL Jr, Rahma OE.

Cancer Immunol Immunother. 2018 Feb;67(2):161-174. doi: 10.1007/s00262-017-2082-z. Epub 2017 Oct 20. Review.

PMID:
29052780
19.

Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ, Sims JS, Hodi FS, Martín-Algarra S, Mandal R, Sharfman WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL Jr, Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N, Chan TA.

Cell. 2017 Nov 2;171(4):934-949.e16. doi: 10.1016/j.cell.2017.09.028. Epub 2017 Oct 12.

20.

Erratum to: Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.

Hsueh EC, DeBloom JR, Lee J, Sussman JJ, Covington KR, Middlebrook B, Johnson C, Cook RW, Slingluff CL Jr, McMasters KM.

J Hematol Oncol. 2017 Oct 5;10(1):160. doi: 10.1186/s13045-017-0524-x. No abstract available.

21.

Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.

Hsueh EC, DeBloom JR, Lee J, Sussman JJ, Covington KR, Middlebrook B, Johnson C, Cook RW, Slingluff CL Jr, McMasters KM.

J Hematol Oncol. 2017 Aug 29;10(1):152. doi: 10.1186/s13045-017-0520-1. Erratum in: J Hematol Oncol. 2017 Oct 5;10 (1):160.

22.

Vaccine-draining lymph nodes of cancer patients for generating anti-cancer antibodies.

Shukla GS, Olson WC, Pero SC, Sun YJ, Carman CL, Slingluff CL Jr, Krag DN.

J Transl Med. 2017 Aug 29;15(1):180. doi: 10.1186/s12967-017-1283-8.

23.

Vaccines targeting helper T cells for cancer immunotherapy.

Melssen M, Slingluff CL Jr.

Curr Opin Immunol. 2017 Aug;47:85-92. doi: 10.1016/j.coi.2017.07.004. Epub 2017 Jul 26. Review.

24.

Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: an argument for the routine use of immunohistochemistry.

Stowman AM, Hickman AW, Gru AA, Slingluff CL Jr.

Melanoma Res. 2017 Aug;27(4):369-376. doi: 10.1097/CMR.0000000000000361. Review.

PMID:
28654548
25.

Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study.

Beasley GM, Hu Y, Youngwirth L, Scheri RP, Salama AK, Rossfeld K, Gardezi S, Agnese DM, Howard JH, Tyler DS, Slingluff CL Jr, Terando AM.

Ann Surg Oncol. 2017 Sep;24(9):2728-2733. doi: 10.1245/s10434-017-5883-6. Epub 2017 May 15.

PMID:
28508145
26.

Surgery investigators funded through the National Institutes of Health: A rebirth.

Hu Y, Edwards BL, Hu K, Brooks KD, Slingluff CL Jr.

Surgery. 2017 Jun;161(6):1482-1488. doi: 10.1016/j.surg.2016.12.004. Epub 2017 Feb 1.

27.

Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.

Salerno EP, Bedognetti D, Mauldin IS, Deacon DH, Shea SM, Pinczewski J, Obeid JM, Coukos G, Wang E, Gajewski TF, Marincola FM, Slingluff CL Jr.

Oncoimmunology. 2016 Oct 18;5(12):e1240857. doi: 10.1080/2162402X.2016.1240857. eCollection 2016.

28.

The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?

Obeid JM, Hu Y, Erdag G, Leick KM, Slingluff CL Jr.

Melanoma Res. 2017 Jun;27(3):211-217. doi: 10.1097/CMR.0000000000000330.

PMID:
28118270
29.

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.

Reuss JE, Kunk PR, Stowman AM, Gru AA, Slingluff CL Jr, Gaughan EM.

J Immunother Cancer. 2016 Dec 20;4:94. doi: 10.1186/s40425-016-0199-9. eCollection 2016.

30.

Statistical controversies in clinical research: early-phase adaptive design for combination immunotherapies.

Wages NA, Slingluff CL Jr, Petroni GR.

Ann Oncol. 2017 Apr 1;28(4):696-701. doi: 10.1093/annonc/mdw681.

31.

PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.

Obeid JM, Erdag G, Smolkin ME, Deacon DH, Patterson JW, Chen L, Bullock TN, Slingluff CL.

Oncoimmunology. 2016 Sep 20;5(11):e1235107. doi: 10.1080/2162402X.2016.1235107. eCollection 2016.

32.

Heterogeneity of CD8+ tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies.

Obeid JM, Wages NA, Hu Y, Deacon DH, Slingluff CL Jr.

Cancer Immunol Immunother. 2017 Jan;66(1):33-43. doi: 10.1007/s00262-016-1908-4. Epub 2016 Oct 21.

33.

Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.

Mauldin IS, Wages NA, Stowman AM, Wang E, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE, Smolkin ME, Chianese-Bullock KA, Clark RA, Petroni GR, Marincola FM, Mullins DW, Slingluff CL Jr.

Cancer Immunol Immunother. 2016 Oct;65(10):1201-12. doi: 10.1007/s00262-016-1880-z. Epub 2016 Aug 13.

34.

Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.

Mauldin IS, Wages NA, Stowman AM, Wang E, Smolkin ME, Olson WC, Deacon DH, Smith KT, Galeassi NV, Chianese-Bullock KA, Dengel LT, Marincola FM, Petroni GR, Mullins DW, Slingluff CL Jr.

Cancer Immunol Immunother. 2016 Oct;65(10):1189-99. doi: 10.1007/s00262-016-1881-y. Epub 2016 Aug 13.

35.

Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.

Ladoire S, Senovilla L, Enot D, Ghiringhelli F, Poirier-Colame V, Chaba K, Erdag G, Schaefer JT, Deacon DH, Zitvogel L, Slingluff CL Jr, Kroemer G.

Oncoimmunology. 2016 Mar 16;5(6):e1160193. doi: 10.1080/2162402X.2016.1160193. eCollection 2016 Jun.

36.

Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.

Benamar M, Guessous F, Du K, Corbett P, Obeid J, Gioeli D, Slingluff CL Jr, Abbas T.

EBioMedicine. 2016 Aug;10:85-100. doi: 10.1016/j.ebiom.2016.06.023. Epub 2016 Jun 16.

37.

Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.

Weber JS, Gibney G, Sullivan RJ, Sosman JA, Slingluff CL Jr, Lawrence DP, Logan TF, Schuchter LM, Nair S, Fecher L, Buchbinder EI, Berghorn E, Ruisi M, Kong G, Jiang J, Horak C, Hodi FS.

Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4. Erratum in: Lancet Oncol. 2016 Jul;17 (7):e270.

38.

Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.

Gentzler R, Hall R, Kunk PR, Gaughan E, Dillon P, Slingluff CL Jr, Rahma OE.

Immunotherapy. 2016 May;8(5):583-600. doi: 10.2217/imt-2015-0029. Review.

PMID:
27140411
39.

From bench to bedside a comprehensive review of pancreatic cancer immunotherapy.

Kunk PR, Bauer TW, Slingluff CL, Rahma OE.

J Immunother Cancer. 2016 Mar 15;4:14. doi: 10.1186/s40425-016-0119-z. eCollection 2016. Review.

40.

Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma.

Jacquelot N, Enot DP, Flament C, Vimond N, Blattner C, Pitt JM, Yamazaki T, Roberti MP, Daillère R, Vétizou M, Poirier-Colame V, Semeraro M, Caignard A, Slingluff CL Jr, Sallusto F, Rusakiewicz S, Weide B, Marabelle A, Kohrt H, Dalle S, Cavalcanti A, Kroemer G, Di Giacomo AM, Maio M, Wong P, Yuan J, Wolchok J, Umansky V, Eggermont A, Zitvogel L.

J Clin Invest. 2016 Mar 1;126(3):921-37. doi: 10.1172/JCI80071. Epub 2016 Feb 8.

41.

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.

Slingluff CL Jr, Petroni GR, Olson WC, Smolkin ME, Chianese-Bullock KA, Mauldin IS, Smith KT, Deacon DH, Varhegyi NE, Donnelly SB, Reed CM, Scott K, Galeassi NV, Grosh WW.

Cancer Immunol Immunother. 2016 Jan;65(1):25-36. doi: 10.1007/s00262-015-1770-9. Epub 2015 Nov 18.

42.

Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma.

Capaldo BJ, Roller D, Axelrod MJ, Koeppel AF, Petricoin EF, Slingluff CL Jr, Weber MJ, Mackey AJ, Gioeli D, Bekiranov S.

PLoS One. 2015 Sep 25;10(9):e0138210. doi: 10.1371/journal.pone.0138210. eCollection 2015.

43.

Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials' experience.

Ramirez AG, Wages NA, Hu Y, Smolkin ME, Slingluff CL Jr.

Cancer Immunol Immunother. 2015 Dec;64(12):1531-9. doi: 10.1007/s00262-015-1758-5. Epub 2015 Sep 21.

44.

Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

Obeid J, Hu Y, Slingluff CL Jr.

Semin Oncol. 2015 Aug;42(4):549-61. doi: 10.1053/j.seminoncol.2015.05.006. Epub 2015 Jun 3. Review.

45.

Long-term outcomes of helper peptide vaccination for metastatic melanoma.

Hu Y, Kim H, Blackwell CM, Slingluff CL Jr.

Ann Surg. 2015 Sep;262(3):456-64; discussion 462-4. doi: 10.1097/SLA.0000000000001419.

46.

Vaccination with Melanoma Helper Peptides Induces Antibody Responses Associated with Improved Overall Survival.

Reed CM, Cresce ND, Mauldin IS, Slingluff CL Jr, Olson WC.

Clin Cancer Res. 2015 Sep 1;21(17):3879-87. doi: 10.1158/1078-0432.CCR-15-0233. Epub 2015 May 12.

47.

Recent trends in National Institutes of Health funding for surgery: 2003 to 2013.

Hu Y, Edwards BL, Brooks KD, Newhook TE, Slingluff CL Jr.

Am J Surg. 2015 Jun;209(6):1083-9. doi: 10.1016/j.amjsurg.2015.01.015. Epub 2015 Mar 21. Review.

48.

Localization of the Sentinel Lymph Node in Melanoma Without Blue Dye.

Hu Y, Melmer PD, Slingluff CL Jr.

Ann Surg. 2016 Mar;263(3):588-92. doi: 10.1097/SLA.0000000000001187.

49.

TLR2/6 agonists and interferon-gamma induce human melanoma cells to produce CXCL10.

Mauldin IS, Wang E, Deacon DH, Olson WC, Bao Y, Slingluff CL Jr.

Int J Cancer. 2015 Sep 15;137(6):1386-96. doi: 10.1002/ijc.29515. Epub 2015 May 29.

50.

Utility of sentinel lymph node biopsy for solitary dermal melanomas.

Hu Y, Shah P, Stukenborg GJ, Slingluff CL Jr.

J Surg Oncol. 2015 Jun;111(7):800-7. doi: 10.1002/jso.23890. Epub 2015 Feb 24.

Supplemental Content

Loading ...
Support Center